As outlined above, cancer genome analyses have not yet defined clusters of mutations typical of oncogenic activation in genes encoding any HIF subunit; to date the clearest evidence for mutational selection on HIF in cancer is an excess of inactivating mutations in HIF-1α in the context of pVHL-defective renal cancer (reviewed in [143]). This evidence concerns the gene VHL and cancer.